close

News

LATEST POSTS from News

TreeFrog Therapeutics secures €30 million from EIB

TreeFrog Therapeutics secures €30 million from EIB TreeFrog Therapeutics, a French biotech specializing in cell therapy, has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson’s Disease to the clinic.  This cell therapy  has…..

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing of its stem cell-based therapy

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing of its stem cell-based therapy First clinical batches of ProtheraCytes® are planned for 2026  CellProthera, a French regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for its…..

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies CRISPR Therapeutics, a Swiss biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a sino-american clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, have concluded a…..

Vivet Therapeutics receives €4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis

Vivet Therapeutics receives €4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis  Funding from French Government as part of the France Health Innovation Plan 2030 Vivet Therapeutics, a French clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders,…..